Inv(16) acute myeloid leukemia cells show an increased sensitivity to cytosine arabinoside in vitro

European Journal of Haematology

Volumn 60, Issue 3, 1998, Pages 161-165

  Tosi, Patrizia ^a,b   Visani, Giuseppe ^a   Ottaviani, Emanuela ^a   Testoni, Nicoletta ^a   Pellacani, Annalisa ^a   Tura, Sante ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

AML; Ara C; Inv(16)

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; DNA; ETOPOSIDE; FLUDARABINE; IDARUBICIN; MITOXANTRONE; TETRAZOLIUM;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; BLAST CELL; CHROMOSOME 16; CHROMOSOME ABERRATION; CHROMOSOME INVERSION; CHROMOSOME TRANSLOCATION 15; CHROMOSOME TRANSLOCATION 8; CLINICAL ARTICLE; COLORIMETRY; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; KARYOTYPE; LEUKEMIA CELL; MALE; PRIORITY JOURNAL;

EID: 0031897537     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1998.tb01017.x     Document Type: Article

References (32)

1. LARSON RA, LEBEAU MM, VARDIMAN JW, TESTA JR, GOLOMB HM, ROWLEY JD. The predictive value of initial cytogenetic studies in 148 adults with acute non-lymphocytic leukemia: a 12-year study (1970-1982). Cancer Genet Cytogenet 1983: 10: 219-236.
2. MACHNIKI JL, BLOOMFIELD CD. Clinical significance of the cytogenetics of acute leukemia. Oncology 1990: 4: 23-30.
3. KEATING MJ, SMITH TL, KANTARJIAN H, et al. Cytogenetic pattern in acute myclogenous leukemia: a major reproducible determinant of outcome. Leukemia 1988: 2: 403-412.
4. FENAUX P, PREUDHOMME C, LAI JL, MOREL P, BEUSCART R, BAUTERS F. Cytogenetics and their prognostic value in de novo acute myeloid leukemia: a report on 283 cases. Br J Haematol 1989: 73: 61-67.
5. LEBEAU MM, LARSON RA, BITTER MM, VARDIMAN JW, GOLOMB HM, ROWLEY JD. Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia. N Engl J Med 1983: 309: 630-636.
6. HAFERLACH T, WINKEMANNM, LÖFFLER H, et al. The abnormal eosinophils are part of the leukemic cell population in acute myelomonocytic leukemia with abnormal eosinophils (AML M4Eo) and carry the pericentric inversion 16: a combination of May-Grünwald-Giemsa staining and fluorescence in situ hybridization. Blood 1996: 87: 2459-2463.
7. KANTARJIAN H, BARLOGIE B, KEATING MJ, et al. Pretreatment cytokinetics in acute myelogenous leukemia. J Clin Invest 1985: 76: 1-6.
8. GHADDAR HM, PLUNKETT W, KANTARJIAN H, et al. Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside. Leukemia 1994: 8: 1269-1274.
9. BLOOMFIELD CD, LAWRENCE D, ARTHUR DC, BKRG DT, SCHIFFER CA, MAYER RJ. Curative impact of intensification with high-dose cytarabine (HiDAC) in acute myeloid leukemia (AML) varies by cytogenetic group. Blood 1994: 84(suppl 1): 111a.
10. FURTH JJ, COHEN SS. Inhibition of mammalian DNA polymerase by the 5′ triphosphate of 9-β-D arabinofurano-sylcytosine and the triphosphate of 9-β-D arabinofurano-syladenine. Cancer Res 1968: 28: 2061-2070.
11. KUFE D, SPRIGGS D, EGAN EM, MUNROE D. Relationships among Ara-CTP pools, formation of (Ara-C) DNA and cytotoxicity of human leukemic cells. Blood 1984: 64: 54-58.
12. KAUFMANN SH. Induction of endonucleolytic DNA cleavage in human acute myclogenous leukemia cells by etoposide, camptothecin and other cytotoxic anticancer drugs. Cancer Res 1989: 49: 5870-5878.
13. GUNJI H, KHARBANDA S, KUFE D. Induction of internucleosomal DNA fragmentation in human myeloid leukemia cells by 1-ß-D-arabinofuranosylcytosine. Cancer Res 1991: 51: 741-747.
14. HANNUN YA. Apoptosis and the dilemma of cancer chemotherapy. Blood 1997: 89: 1845-1853.
15. LAURIA F, RASPADORI D, MARTINELLI G, et al. Increased expression of myeloid markers in adult acute lymphoblastic leukemia patients: diagnostic and prognostic implications. Br J Haematol 1994: 87: 286-292.
16. SCUDIERO D, SHOEMAKER RH, PAUL K, et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 1988: 48: 4827-4833.
17. TOSI P, VISANI G, OTTAVIANI E, MANIFROI S, ZINZANI PL, TURA S. Fludarabine+Ara-C+G-CSF: cytotoxic effect and induction of apoptosis on fresh acute myeloid leukemia cells. Leukemia 1994: 8: 2076-2082.
18. PONDA CK, CHONDURY K, NEOGY K. Characterization of DNA binding proteins released from S180 chromatin during brief digestion with DNAsc I. Mol Cell Biochem 1987: 78: 101-108.
19. NICOLETTI I, MIGLIORATI G, PAGLIACCI MC, GRIGNANI F, RICCARDI C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Meth 1991: 139: 271-279.
20. LARSON RA, WILLIAMS SF, LEBEAU MM, BITTER MA, VARDIMAN JW, ROWLEY JD. Acute myelomonocytic leukemia with abnormal eosinophils and inv(16) or t(16:16) has a favorable prognosis. Blood 1986: 68: 1242-1249.
21. EARLY AP, PREISLER HD, SLOCUM H. A pilot study of high-dose 1-ß-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology. Cancer Res 1982: 42: 1587-1594.
22. MARLTON P, KEATING M, KANTARJIAN H, et al. Cytogenetic and clinical correlates in AML patients with abnormalities of chromosome 16. Leukemia 1995: 9: 965-971.
23. HOLMES R, KEATING MJ, CORK A, et al. A unique pattern of central nervous system leukemia in acute myelomonocytic leukemia associated with inv(16) (p13q22). Blood 1985: 65: 1071-1078.
24. PIETERS R, HUISMANS DR, LOONEN AH, et al. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet 1991: 338: 399-403.
25. TOSI P, VISANI G, OTTAVIANI E, MANFROI S, TURA S. Biological and clinical significance of in vitro prednisolone resistance in adult acute lymphoblastic leukaemia. Eur J Haematol 1996: 56: 134-141.
26. LIU P, TARLÈ SA, HAJRA A, et al. Fusion between transcription factor CBF ß/PEBP2ß and a myosin heavy chain in acute myeloid leukemia. Science 1993: 26: 1041-1044.
27. MARLTON P, CLAXTON DF, LIU P, et al. Molecular characterization of 16p deletions associated with inversion 16 defines the critical fusion for leukemogenesis. Blood 1995: 85: 772-779.
28. LACOMBE F, BELLOC F, DUMAIN P, et al. Detection of cytarabine resistance in patients with acute myclogenous leukemia using flow cytometry. Blood 1994: 84: 716-723.
29. CHIBA P, TIHAU T, EHER R, et al. Effect of cell growth and differentiation on 1-β-arabinofuranosylcytosine metabolism in myeloid cells. Br J Haematol 1989: 71: 451-455.
30. LIU ET, DODGE R, MYER A, et al. De novo acute myeloid leukemias harboring ras mutations exhibit preferential sensitivity to dose-intensive cytarabine as consolidation therapy. Blood 1995: 86 (suppl 1): 598a.
31. Koo HM, MONKS A, MIKHEEV A, et al. Enhanced sensitivity to 1-ß-D arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes. Cancer Res 1996: 56: 5211-5216.
32. NEUBAUER A, DODGE RK, GEORGE SL, et al. Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. Blood 1994: 83: 1603-1611.